Belvedere Trading’s Cartesian Therapeutics RNAC Stock Holding History

Belvedere Trading’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,200	Closed	-$8.98K	–	891
2024 Q2	$8.98K	Buy	+10,200	New	+$243K	﹤0.01%	602
2022 Q4	–	Sell	-1,710	Closed	-$87K	–	1196
2022 Q3	$87K	Sell	1,710 -613	-26%	-$33.7K	﹤0.01%	197
2022 Q2	$116K	Buy	+2,323	New	+$68.9K	﹤0.01%	240

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's RNAC Position: Q1 2023 in Review

Belvedere Trading sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 690 shares — an estimated $23.4K sold.

Belvedere Trading first reported a position in RNAC in Q3 2022 and held it in 2 quarters. The position peaked at $75K in Q3 2022. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

Belvedere Trading reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 690 Cartesian Therapeutics shares in Q1 2023, an estimated $23.4K.
Belvedere Trading first reported a position in Cartesian Therapeutics in Q3 2022 and held it in 2 quarters.
Belvedere Trading's Cartesian Therapeutics position peaked at $75K in Q3 2022.
93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.